Discovery and saturation analysis of cancer genes across 21 tumour types
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, the dysregulation of chromatin looping may be causally related to carcinogenesis (Extended Data Fig. 7a) 31,32.”
From The structural basis for cohesin–CTCF-anchored loops (2020) · cites this paper as [31]
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“The process of tumor development is strongly related to the dysfunctions caused by TP53 mutations.3,4”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
In the citing paper
“Most TP53 mutations are missense mutations located in the DBD.3,4,203,205,380”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“(5) Chromatin regulation—Five genes are associated with chromatin regulation.”
Self-citationMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053 · cited 1×
“(4) Genome stability—Six genes encode proteins related to genome stability.”
BackgroundSelf-citationPan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870 · cited 1×
“(7) RNA processing—Three genes are associated with RNA processing and metabolism.”
BackgroundSelf-citationMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 4×
“We ask: (1) Can large-scale genomic analysis across tumor types reliably identify all known cancer genes? (2) Will it reveal many new candidate cancer genes? (3) How far do we stand from having a complete catalog of cancer genes – at least those of intermediate frequency? We used rigorous statistical methods to enumer…”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 801–900 of 1,017
Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations
Nikolaev, S. I., Garieri, M., Santoni, F. A., Falconnet, E., Ribaux, P., Guipponi, M., Murray, A., Groet, J., Giarin, E., Basso, G., et al. (2014) · Nature Communications · doi:10.1038/ncomms5654 · Cited by 64
Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer
Park, H., Cho, S., Kim, H., Na, D., Han, J. Y., Chae, J., Park, C., Park, O.-K., Min, S., Kang, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507491112 · Cited by 82
Callari, M., Batra, A. S., Batra, R. N., Sammut, S., Greenwood, W., Clifford, H., Hercus, C., Chin, S., Bruna, A., Rueda, O. M., et al. (2018) · BMC Genomics · doi:10.1186/s12864-017-4414-y · Cited by 64
“At the same time, sequencing based technology has become the standard for cancer molecular characterization at the genomic, transcriptomic and epigenomic levels [14 – 16].”
BackgroundPalindromic Molecule Beacon-Based Cascade Amplification for Colorimetric Detection of Cancer Genes
Shen, Z., Li, F., Jiang, Y.-F., Chen, C., Xu, H. Y., Li, C., Yang, Z., & Wu, Z. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04895 · Cited by 65
Helman, E., Nguyen, M., Karlovich, C., Despain, D., Choquette, A. K., Spira, A. I., Yu, H. A., Camidge, D. R., Harding, T. C., Lanman, R. B., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.07.008 · Cited by 68
Marampon, F., Ciccarelli, C., & ZANI, B. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102530 · Cited by 78
Murali, I., Kasar, S. N., Naeem, A. S., Tyekucheva, S., Khalsa, J. K., Thrash, E. M., Itchaki, G., Livitz, D. G., Leshchiner, I., Dong, S., et al. (2021) · Blood · doi:10.1182/blood.2020006765 · Cited by 73
Self-citationLiu, S., Zhao, Q., Peng, C. Y., Mao, Q., Wu, F., Zhang, F., Feng, Q., He, G., & Han, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113359 · Cited by 67
Rathinaswamy, M. K., Dalwadi, U., Fleming, K. D., Adams, C., Stariha, J. T. B., Pardon, E., Baek, M., Vadas, O., DiMaio, F., Steyaert, J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj4282 · Cited by 62
Guan, L., Nambiar, D. K., Cao, H., Viswanathan, V., Kwok, S., Hui, A. B., Hou, Y., Hildebrand, R., von Eyben, R., Holmes, B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1903 · Cited by 69
Rethinking pheochromocytomas and paragangliomas from a genomic perspective
Castro‐Vega, L. J., Lussey‐Lepoutre, C., Gimenez‐Roqueplo, A., & Favier, J. (2015) · Oncogene · doi:10.1038/onc.2015.172 · Cited by 84
Concise Review: Dedifferentiation Meets Cancer Development: Proof of Concept for Epigenetic Cancer
Yamada, Y., Haga, H., & Yamada, Y. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0090 · Cited by 78
Mutational profiling of kinases in glioblastoma
Bleeker, F. E., Lamba, S., Zanon, C., Molenaar, R. J., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., Vandertop, W. P., Leenstra, S., Noorden, C. J. F. V., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-718 · Cited by 76
Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Satoh, Y., Ishii, N., & Aoki, M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0927-t · Cited by 69
Guerini‐Rocco, E., Piscuoglio, S., Ng, C. K. Y., Geyer, F. C., Filippo, M. R. D., Eberle, C. A., Akram, M. M., Fusco, N., Ichihara, S., Sakr, R. A., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4691 · Cited by 70
Swaroop, A., Oyer, J. A., Will, C., Huang, X., Yu, W., Troche, C., Bulic, M., Durham, B. H., Wen, Q. J., Crispino, J. D., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0474-y · Cited by 68
“Additionally, mutations in the genes encoding epigenetic regulators are often detected in ALL (4–7).”
Cohesin SA1 and SA2 are RNA binding proteins that localize to RNA containing regions on DNA
Pan, H., Jin, M., Ghadiyaram, A., Kaur, P., Miller, H. E., Ta, H. M., Liu, M., Fan, Y., Mahn, C., Gorthi, A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa284 · Cited by 64
“Importantly, based on the analysis of somatic point mutations in exome sequences from 4742 human cancers, SA2 has been identified as 1 of only 12 genes that are significantly mutated in four or more cancer types (9–11).”
BackgroundPatterns of genomic evolution in advanced melanoma
Birkeland, E. E., Zhang, S., Poduval, D. B., Geisler, J., Nakken, S., Vodák, D., Meza‐Zepeda, L. A., Hovig, E. J., Myklebost, O., Knappskog, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05063-1 · Cited by 66
Li, X., Li, Q., Ju, L., Zhao, C. N., Zhao, L., Du, J., Wang, Y., Zheng, L., Song, B., Li, L., et al. (2020) · Hepatology · doi:10.1002/hep.31594 · Cited by 62
The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis
Liu, P., Luo, G., Dodson, M. B., Schmidlin, C. J., Wei, Y., Kerimoğlu, B., Ooi, A., Chapman, E., Garcia, J. G. N., & Zhang, D. D. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101766 · Cited by 69
Xu, J., Yu, X., Martin, T. C., Bansal, A., Cheung, K., Lubin, A., Stratikopoulos, E., Cahuzac, K. M., Wang, L., Xie, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0815 · Cited by 65
Molecular changes in endometriosis-associated ovarian clear cell carcinoma
Worley, M. J., Liu, S., Hua, Y., Kwok, J. S.-L., Samuel, A., Hou, L., Shoni, M., Lu, S., Sandberg, E. M., Keryan, A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.011 · Cited by 63
Hofman, I. J., van Duin, M., Bruyne, E. D., Fancello, L., Mulligan, G., Geerdens, E., Garelli, E., Mancini, C., Lemmens, H., Delforge, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.370 · Cited by 64
A whole-animal platform to advance a clinical kinase inhibitor into new disease space
Sonoshita, M., Scopton, A. P., Ung, P. M. U., Murray, M. A., Silber, L., Maldonado, A. Y., Real, A. M., Schlessinger, A., Cagan, R. L., & Dar, A. C. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2556 · Cited by 74
The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities
Srivastava, S., Ghosh, S., Kagan, J., Mazurchuk, R. V., Boja, E. S., Chuaqui, R. F., Chavarria-Johnson, E., Davidsen, T. M., Eary, J. F., Haim, T., et al. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.06.007 · Cited by 64
Zhou, Y., Liu, W., Xu, Z., Zhu, H., Xiao, D., Su, W., Zeng, R., Feng, Y., Duan, Y., Zhou, J., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.08.012 · Cited by 65
Systemic candidiasis in four foals
Reilly, L. K., & Palmer, J. E. (1994) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.1994.205.03.464 · Cited by 65
Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation
Buccitelli, C., Salgueiro, L., Rowald, K., Sotillo, R., Mardin, B. R., & Korbel, J. O. (2017) · Genome Research · doi:10.1101/gr.212225.116 · Cited by 64
“…re-sults are consistent with TP53 mutation and loss and MYC amplification, these being common events seen in tumors with complex karyotypes including UCEC and COAD-READ (The Cancer Genome Atlas Network 2012; The Cancer Genome Atlas Research Network 2013; Zack et al. 2013; Lawrence et al. 2014).”
BackgroundRoth, T. L., & Marson, A. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032626 · Cited by 79
Tumour- associated autoantibodies as prognostic cancer biomarkers- a review
Sexauer, D., Gray, E. S., & Zaenker, P. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103041 · Cited by 64
Chen, L., Chen, W., Mysliwski, M., Serio, J., Ropa, J. P., Abulwerdi, F. A., Chan, R. J., Patel, J. P., Tallman, M. S., Paietta, E. M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.18 · Cited by 64
Fadlullah, M. Z. H., Chiang, I. K., Dionne, K. R., Yee, P. S., Gan, C. P., Sam, K. K., Tiong, K. H., Ng, K. W., Martín, D., Lim, K. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8533 · Cited by 68
Rnd3 in Cancer: A Review of the Evidence for Tumor Promoter or Suppressor
Paysan, L., Piquet, L., Saltel, F., & Moreau, V. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0164 · Cited by 68
Riesco‐Eizaguirre, G., & Santisteban, P. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0202 · Cited by 71
Yu, O. M., Benitez, J. A., Plouffe, S. W., Ryback, D., Klein, A., Smith, J., Greenbaum, J., Delatte, B., Rao, A., Guan, K.-L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0301-5 · Cited by 62
“…genes across 21 tumor types identified 33 genes not previously shown to be significantly mutated in cancer, including not only RhoA and a RhoA GAP, but also myocardin (with mutations in the region of putative interaction with YAP) substantiating the role of this signaling pathway in cancer 78 .”
Alexiadis, M., Rowley, S. M., Chu, S., Leung, D. T. H., Stewart, C. J. R., Amarasinghe, K. C., Campbell, I., & Fuller, P. J. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0359 · Cited by 70
Advances in Small-Cell Lung Cancer (SCLC) Translational Research
Drapkin, B. J., & Rudin, C. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038240 · Cited by 68
“Given a somatic mutation burden of ∼10 per Mb,∼900 samples would be required to saturate for mutations with 5% recurrence, and more than 3000 samples to saturate at 2% (Lawrence et al. 2014).”
BackgroundAncestry-specific predisposing germline variants in cancer
Oak, N., Cherniack, A. D., Mashl, R. J., TCGA Analysis Network, Hirsch, F. R., Ding, L., Beroukhim, R., Gumus, Z. H., Plon, S. E., & Huang, K. (2020) · Genome Medicine · doi:10.1186/s13073-020-00744-3 · Cited by 69
OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action
Schroeder, M. P., Rubio-Perez, C., Tamborero, D., Gonzalez-Perez, A., & Lopez-Bigas, N. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu467 · Cited by 60
Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia
Tan, S. H., Bertulfo, F. C., & Sanda, T. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00218 · Cited by 66
The Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms
Zhang, J., & Zhang, S. (2016) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2016.2640963 · Cited by 67
“Although some comparative studies among multiple cancer types have been developed in recent years [41], [66], [81], [82], [83], more further explorations are needed and more comprehensive results are expected.”
BackgroundTAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia
Sanda, T., & Leong, W. Z. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.06.001 · Cited by 71
Karras, P., Riveiro‐Falkenbach, E., Cañón, E., Tejedo, C., Calvo, T. G., Martínez-Herranz, R., Alonso‐Curbelo, D., Cifdaloz, M., Pérez‐Guijarro, E., Goméz-López, G., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.008 · Cited by 71
Genomic and molecular alterations in human inflammatory bowel disease‐associated colorectal cancer
Müller, M., Hansmannel, F., Arnone, D., Choukour, M., Ndiaye, N. C., Kökten, T., Houlgatte, R., & Peyrin‐Biroulet, L. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620919254 · Cited by 67
Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity
Das, P., & Taube, J. H. (2020) · Cancers · doi:10.3390/cancers12102792 · Cited by 65
Mechanisms and regulation of replication fork reversal
Adolph, M. B., & Cortez, D. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103731 · Cited by 66
The role of mutations in epigenetic regulators in myeloid malignancies
Woods, B. A., & Levine, R. L. (2015) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 60
Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data
Kumar, R. D., Searleman, A. C., Swamidass, S. J., Griffith, O. L., & Bose, R. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv430 · Cited by 69
Lee, J. Y., Schizas, M., Geyer, F. C., Selenica, P., Piscuoglio, S., Sakr, R. A., Ng, C. K. Y., Carniello, J. V. S., Towers, R., Giri, D. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1103 · Cited by 62
Different mutation profiles between epithelium and stroma in endometriosis and normal endometrium
Suda, K., Nakaoka, H., Yoshihara, K., Ishiguro, T., Adachi, S., Kase, H., Motoyama, T., Inoue, I., & Enomoto, T. (2019) · Human Reproduction · doi:10.1093/humrep/dez155 · Cited by 64
AlQuraishi, M., Koytiger, G., Jenney, A., MacBeath, G., & Sorger, P. K. (2014) · Nature Genetics · doi:10.1038/ng.3138 · Cited by 59
“TCGA and similar projects have generated extensive data on the mutational landscape of tumors 1 .”
BackgroundThe multifaceted roles of cohesin in cancer
Nardo, M. D., Pallotta, M. M., & Musio, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02321-5 · Cited by 65
Multiancestry genomic and transcriptomic analysis of gastric cancer
Totoki, Y., Saito-Adachi, M., Shiraishi, Y., Komura, D., Nakamura, H. K., Suzuki, A., Tatsuno, K., Rokutan, H., Hama, N., Yamamoto, S., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01333-x · Cited by 71
Tyburczy, M. E., Jóźwiak, S., Malinowska, I. A., Chekaluk, Y. I., Pugh, T. J., Wu, C., Nussbaum, R. L., Seepo, S., Dzik, T., Kotulska, K., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu597 · Cited by 58
Sun, Z., Wang, C., Lawson, D. A., Kwek, S. S., Velozo, H. G., Owyong, M., Lai, M.-D., Fong, L. H., Wilson, M. W., Su, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23760 · Cited by 58
Bone marrow transplantation generates T cell–dependent control of myeloma in mice
Vučković, S., Minnie, S. A., Smith, D. D., Gartlan, K. H., Watkins, T. S., Markey, K. A., Mukhopadhyay, P., Guillerey, C., Kuns, R. D., Locke, K. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98888 · Cited by 63
Cha, S., Lee, E., & Won, H. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00303-y · Cited by 60
Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations
AlDoughaim, M., Alsuhebany, N., Alzahrani, M., Alqahtani, T., Alghamdi, S. S., Badreldin, H. A., & Alshaykh, H. A. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241298541 · Cited by 87
Recurrent RHOA mutations in pediatric B urkitt lymphoma treated according to the NHL‐BFM protocols
Rohde, M., Richter, J., Schlesner, M., Betts, M. J., Claviez, A., Bonn, B. R., Zimmermann, M., Damm‐Welk, C., Russell, R. B., Borkhardt, A., et al. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22202 · Cited by 66
“However, the sites affected by mutations in BL as described herein were not found to be recurrently mutated in PTCL. Mutations of RHOA have also been detected in solid tumors, particularly head and neck tumors (Lawrence et al., 2014).”
MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis
Jia, P., Wang, Q., Chen, Q., Hutchinson, K. E., Pao, W. J., & Zhao, Z. (2014) · Genome biology · doi:10.1186/preaccept-1822061407140231 · Cited by 67
Kim, J.-S., He, X., Orr, B., Wutz, G., Hill, V. K., Peters, J., Compton, D. A., & Waldman, T. A. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005865 · Cited by 65
Cheng, F., Murray, J. L., Zhao, J., Sheng, J., Zhao, Z., & Rubin, D. H. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005074 · Cited by 58
Mutational signatures and mutable motifs in cancer genomes
Rogozin, I. B., Pavlov, Y. I., Goncearenco, A., De, S., Lada, A. G., Poliakov, E., Panchenko, A. R., & Cooper, D. N. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx049 · Cited by 58
Characterization of background noise in capture-based targeted sequencing data
Park, G., Park, J. K., Shin, S., Jeon, H.-J., Kim, N. K. D., Kim, Y. J., Shin, H., Lee, E., Lee, K. H., Son, D., et al. (2017) · Genome biology · doi:10.1186/s13059-017-1275-2 · Cited by 63
Using macropinocytosis for intracellular delivery of therapeutic nucleic acids to tumour cells
Desai, A. S., Hunter, M. R., & Kapustin, A. N. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2018.0156 · Cited by 63
Concepts in solid tumor evolution
Sidow, A., & Spies, N. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.02.001 · Cited by 69
RBM10: Structure, functions, and associated diseases
Inoue, A. (2021) · Gene · doi:10.1016/j.gene.2021.145463 · Cited by 62
Chisanga, D., Keerthikumar, S., Pathan, M., Ariyaratne, D., Kalra, H., Boukouris, S., Mathew, N. A., Saffar, H. A., Gangoda, L., Ang, C.-S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1097 · Cited by 57
Sokolova, V., Fiorino, A., Zoni, E., Crippa, E., Reid, J. F., Gariboldi, M., & Pierotti, M. A. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25051 · Cited by 57
“Mutations at TGFBR2, ACVR2, and their SMAD effectors occur at a significant frequency (Lao and Grady, 2011; Network, 2012; Lawrence et al., 2014), and TGFBR2, together with KRAS mutations is associated with late adenoma malignant transformation (Grady et al., 1998).”
BackgroundRajkumar, S., & Watson, I. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.195 · Cited by 57
“…actionable and driver mutations without sequencing the estimated 5300 samples required to identify driver mutations in X2% of melanoma patients (Lawrence et al, 2014), studies have cross-referenced the COSMIC mutation database that compiles mutation data from all nextgeneration sequencing…”
BackgroundMethodKiyotani, K., Mai, T. H., & Nakamura, Y. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2016.141 · Cited by 57
DNA Repair Pathway Alterations in Bladder Cancer
Mouw, K. W. (2017) · Cancers · doi:10.3390/cancers9040028 · Cited by 62
SWI/SNF catalytic subunits’ switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells
Wu, S., Fatkhutdinov, N., Fukumoto, T., Bitler, B. G., Park, P. H., Kossenkov, A. V., Trizzino, M., Tang, H., Zhang, L., Gardini, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06656-6 · Cited by 58
Guide snoRNAs: Drivers or Passengers in Human Disease?
Deogharia, M., & Majumder, M. (2018) · Biology · doi:10.3390/biology8010001 · Cited by 56
LOTUS: A single- and multitask machine learning algorithm for the prediction of cancer driver genes
Collier, O., Stoven, V., & Vert, J. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007381 · Cited by 66
Identification of relevant genetic alterations in cancer using topological data analysis
Rabadán, R., Mohamedi, Y., Rubin, U., Chu, T., Alghalith, A. N., Elliott, O., Arnes, L., Cal, S., Obaya, Á. J., Levine, A. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17659-7 · Cited by 73
Identification of responders to immune checkpoint therapy: Which biomarkers have the highest value?
Liebl, M. C., & Hofmann, T. G. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15992 · Cited by 58
Langille, E. R., Al‐Zahrani, K. N., Ma, Z., Liang, M., Uusküla-Reimand, L., Espín, R., Teng, K., Malik, A., Bergholtz, H., Ghamrasni, S. E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0865 · Cited by 61
USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity
Li, J., Wang, Y., Luo, Y., Liu, Y., Yi, Y., Li, J., Pan, Y., Li, W., You, W., Hu, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35557-y · Cited by 65
“The notion that Beclin 1 can function as a tumor suppressor protein is supported by several well-known studies, including the observations that endogenous Beclin 1 protein expression is frequently low in human breast epithelial carcinoma cell lines and tissue, but is expressed ubiquitously at high levels in normal bre…”
InfluentialChen, Y., Wang, Z., Jin, Y., Zhao, Q., Liu, Z., Zuo, Z., Ju, H., Cui, C., Yao, J., Zhang, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.016 · Cited by 60
Knol, J. C., Lyu, M., Böttger, F., Monteiro, M. N., Pham, T. V., Rolfs, F., Vallés‐Martí, A., Schelfhorst, T., Haas, R. R. D. G., Bijnsdorp, I. V., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.003 · Cited by 68
Marquard, A. M., Birkbak, N. J., Thomas, C. E., Favero, F., Krzystanek, M., Lefebvre, C., Ferté, C., Jamal-Hanjani, M., Wilson, G. A., Shafi, S., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0130-0 · Cited by 56
Mutant HRAS as novel target for MEK and mTOR inhibitors
Kiessling, M. K., Curioni-Fontecedro, A., Samaras, P., Atrott, K., Cosin-Roger, J., Lang, S., Scharl, M., & Rogler, G. (2015) · Oncotarget · doi:10.18632/oncotarget.5619 · Cited by 56
DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders
Sato, H., Wheat, J. C., Steidl, U. G., & Ito, K. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00187 · Cited by 64
Non-coding genetic variation in cancer
Cuykendall, T. N., Rubin, M. A., & Khurana, E. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2016.12.017 · Cited by 62
Pan-urologic cancer genomic subtypes that transcend tissue of origin
Chen, F., Zhang, Y., Bossé, D., Lalani, A. A., Hakimi, A. A., Hsieh, J. J.-D., Choueiri, T. K., Gibbons, D. L., Ittmann, M., & Creighton, C. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00289-x · Cited by 63
The whole-genome panorama of cancer drivers
Sabarinathan, R., Pich, O., Martincorena, I., Rubio-Perez, C., Juul, M., Wala, J., Schumacher, S., Shapira, O., Sidiropoulos, N., Waszak, S. M., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/190330 · Cited by 54
“Second, the statistical power of the PCAWG cohort to discover driver GEs is limited; some bona fide cancer genes could be mutated at frequencies below the detection threshold of current driver discovery methods 17,19 .”
BackgroundSelf-citationUnderstanding oncogenicity of cancer driver genes and mutations in the cancer genomics era
Porta‐Pardo, E., Valencia, A., & Godzik, A. (2020) · FEBS Letters · doi:10.1002/1873-3468.13781 · Cited by 68
LeBlanc, A. K., Mazcko, C. N., Cherukuri, A., Berger, E. P., Kisseberth, W. C., Brown, M. E., Lana, S. E., Weishaar, K. M., Flesner, B. K., Bryan, J. N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0315 · Cited by 67
Leveraging epigenetics to enhance the efficacy of immunotherapy
Licht, J. D., & Bennett, R. L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01100-x · Cited by 57
Coleman, N., Moyers, J. T., Harbery, A., Vivanco, I., & Yap, T. A. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s305068 · Cited by 71
Creaney, J., Patch, A., Addala, V., Sneddon, S., Nones, K., Dick, I. M., Lee, G., Newell, F., Rouse, E. J., Naeini, M. M., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01060-8 · Cited by 67
Cahuzac, K. M., Lubin, A., Bosch, K. N., Stokes, N., Schoenfeld, S., Zhou, R. W., Lemon, H., Asara, J. M., & Parsons, R. E. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112536 · Cited by 67
New horizons at the interface of artificial intelligence and translational cancer research
Yates, J., & Allen, E. M. V. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.018 · Cited by 63
Qiu, L., Wu, J., Pan, C., Tan, X.-R., Lin, J., Liu, R., Chen, S., Geng, R., & Huang, W. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.402 · Cited by 63
Cheng, F., Zhao, J., Fooksa, M., & Zhao, Z. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw007 · Cited by 62
“19 identified 224 SMGs from 4742 human cancer genomes across 21 cancer types using the MutSig method.”
MethodIntegrated genetic and pharmacologic interrogation of rare cancers
Hong, A. L., Tseng, Y., Cowley, G. S., Jonas, O. H., Cheah, J. H., Kynnap, B. D., Doshi, M. B., Oh, C., Meyer, S. C., Church, A. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11987 · Cited by 59
Self-citationImmunotherapeutic Approaches to Sarcoma
Burgess, M. A., & Tawbi, H. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0345-5 · Cited by 65
Fang, L.-M., Li, B., Guan, J.-J., Xu, H., Shen, G., Gao, Q., & Qin, Z. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.25 · Cited by 56
Cross-talk between Lysine-Modifying Enzymes Controls Site-Specific DNA Amplifications
Mishra, S., Rechem, C. V., Pal, S., Clarke, T. L., Chakraborty, D., Mahan, S. D., Black, J. C., Murphy, S. E., Lawrence, M. S., Daniels, D. L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.018 · Cited by 60
Self-citation
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Venue
- Nature
- Published
- 2014-01
- Volume
- 505
- Issue
- 7484
- Pages
- 495-501
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4048962
- OpenAlex
- W2114031931
- Cited by
- 3,096
- References
- 13
- Citations by year
- 2026: 103 · 2025: 188 · 2024: 202 · 2023: 223 · 2022: 235 · 2021: 241 · 2020: 277 · 2019: 268 · 2018: 264 · 2017: 312 · 2016: 305 · 2015: 291 · 2014: 177
- FWCI
- 116.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R01CA157304)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- cancer genes, somatic point mutations, cancer types, saturation analysis, mutation frequency, exome sequencing, sample size determination, mutation rate heterogeneity, cancer genomics
- MeSH terms
- Chromatin, DNA Mutational Analysis, Humans, Neoplasms, RNA Processing, Post-Transcriptional, Genome, Human, Case-Control Studies, Apoptosis, Point Mutation, Sample Size, Genomics, Genomic Instability, Cell Proliferation, Genes, Neoplasm, Immune Evasion, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.